Uncategorized
FDA approves Simbrinza suspension to reduce IOP
The U.S. Food and Drug Administration approved Simbrinza suspension, a fixed-dose combination therapy without a beta blocker, to reduce IOP in patients with primary open-angle glaucoma or ocular hypertension, according to a press release from Alcon.The suspension combines brimonidine tartrate 0.2%, an alpha 2 adrenergic receptor agonist, and brinzolamide 1%, a carbonic anhydrase inhibitor, in a multi-dose bottle, which patients are to administer three times each day.